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Abstract 
This paper by adopting the Software on Market Analysis and Restrictions on Trade assessed the ex-ante impact of 
tariff elimination under the European—Vietnam free trade agreement (EVFTA) on Vietnam’s pharmaceutical imports 
from the EU based on two scenarios. The results showed that although Vietnam’s tariff removal for the EU’s medi-
cines would not result in a significant increase in Vietnam’s imports from the EU, Vietnam’s deeper integration with 
ASEAN + 3 and TPP (the Trans-Pacific Partnership) nations would affect quite slightly on its imports from the EU. 
Therefore, the EU would be still the most important and biggest source of pharmaceuticals for Vietnam in the near 
future. In addition, there might be an uneven distribution in Vietnam’s import increases by the EU nation, pharmaceu-
tical group and product. The simulation results also pointed out that the EVFTA’s trade creation effect would be higher 
than trade diversion effect and therefore the agreement would improve welfare of Vietnam. When Vietnam extends 
its coverage of tariff elimination to also TPP and ASEAN + 3, Vietnam’s welfare would potentially increase more but 
Vietnam would face with the relatively high increases of pharmaceutical imports from not only the EU but also the US, 
Australia, South Korea, Thailand and China. Bases on these results, the paper argued that both the Vietnamese govern-
ment and pharmaceutical enterprises should not neglect the EVFTA and its impacts on the pharmaceutical sector, 
and perceive clearly the uneven distribution of Vietnam’s import changes from the EU by nation and by product to 
design appropriate business and investment strategy. In addition, Vietnam should take measures to diversify its Euro-
pean import markets to be less dependent on the traditional ones in the current context of the EU. Finally, Vietnam 
should promote the integration in the pharmaceutical sector with all three groups of nations, especially ASEAN and 
ASEAN’s key partners, to reduce trade diversion effect and raise the welfare of Vietnam, given that Vietnam should 
consider carefully the point of time to remove tariff for each group to avoid the sudden increase in its pharmaceutical 
imports.
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Background
Being a tropical monsoon climate country, a great deal of 
diseases are more likely to be easily occurred in Vietnam, 
whose population ranks 14th in the world (CIA 2014) 
and population density is high among the South East 
Asian nations (EVBN 2014). Vietnam is also facing with 
the risk of environmental pollution and lack of safety in 
the daily food. However, in the recent years, Vietnam’s 
living standard, awareness of healthcare issues and the 
access to medicines have been improved. All of the above 
factors have resulted in an increasing demand for medi-
cines in Vietnam and made Vietnam become a highly 
lucrative pharmaceutical market with the highest growth 
rate among the South East Asian nations (Vu 2014).
The pharmaceutical market of Vietnam has been char-
acterized by imported drugs, which have meet nearly 
60  % of the total domestic consumption in the recent 
years (Nguyen 2014b; Maybank KimEng 2015). Among 
the pharmaceutical import markets of Vietnam, the 
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European Union (EU) has traditionally been the largest 
one. Overtime, imports from the EU of Vietnam have 
continuously increased and reached USD 1.1 billion, 
accounting for nearly 51  % of Vietnam’s total pharma-
ceutical imports in 2014 (ITC 2016). Pharmaceuticals 
are also the second biggest products Vietnam imported 
from the EU during the period 2001–2014 and have sig-
nificantly contributed to meet the domestic demand, take 
care of the people’s health and stabilize the socio-eco-
nomic development of Vietnam.
On 2nd December 2015, Vietnam and the EU signed 
the Declaration on the conclusion of the European—Viet-
nam Free Trade Agreement (EVFTA) negotiation and 
on 1st February 2016, the full text of the agreement was 
officially announced. The way ahead now for both parties 
is to conduct legal review, translate the EVFTA into the 
EU’s official languages and Vietnamese, approve and rat-
ify the agreement. According to information published so 
far, Vietnam commits to eliminate tariff for about a half 
of pharmaceuticals’ tariff lines immediately on the date 
EVFTA enters into force and the rest shall be removed 
within 10  years (Vu 2015). As the EU is Vietnam’s larg-
est pharmaceutical import market, this tariff elimination 
is likely to affect considerably Vietnam’s pharmaceutical 
imports and healthcare industry. Therefore, understand-
ing the impact of tariff removal under the EVFTA on 
Vietnam’s pharmaceutical imports is vital for both the 
Vietnamese government and enterprises, contributing to 
support them to better and more efficiently prepare for 
integration with the EU and avoid adverse effects on the 
development of this industry.
In Vietnam, while the impact of TPP (the Trans-Pacific 
Partnership) on Vietnam’s economy is a common topic, 
the impact of EVFTA is neglected by both researchers 
and enterprises. So far, there are just some comprehen-
sive research on the impact of the EVFTA on Vietnam’s 
economy such as those conducted by Philip et al. (2011), 
Baker et  al. (2014), and Nguyen (2014a). More impor-
tantly, there is no previous literature quantifying the 
impact of the EVFTA on Vietnam’s trade in pharmaceu-
ticals while this product is among the top traded goods 
between Vietnam and the EU, and the EU is the biggest 
source supplying this product to Vietnam. To fill this gap, 
this paper, by adopting the Software on Market Analy-
sis and Restrictions on Trade (SMART), helps answer 
how the EVFTA potentially affects Vietnam’s imports of 
pharmaceuticals from the EU. The paper is structured as 
below. After the introduction, the second part reviews 
some past literature, and the next two parts analyze key 
features in Vietnam’s pharmaceutical imports from the 
EU and tariff reduction commitments under the EVFTA. 
The methodology and data are presented in the fifth part 
and then results on potential impacts of the EVFTA are 
shown in the sixth part. The paper draws out some impli-
cations, which are essential for Vietnam to better prepare 
for as well as take advantages of this upcoming ambi-
tious free trade agreement (FTA) in the final part before 
coming up with the conclusions. The pioneering study in 
Vietnam adopting the SMART to examine and quantify 
the impacts of the EVFTA on Vietnam’s imports of phar-
maceuticals from the EU is the biggest contribution of 
this paper.
Literature review
Literature review on trade impacts of a FTA
In the context of Doha Round failure, FTAs are consid-
ered the second best option for nations to promote inter-
national economic integration. Together with the strong 
development of FTAs all over the world, and wider and 
deeper coverage of FTA negotiations, the contents of a 
new-generation FTA are now not limited to trade liberal-
ization but also extends to other more complicated issues 
such as investment, government procurement, intellec-
tual property right, environment and labor (Matsushita 
2010; VCCI et  al. 2012). However, the key background 
and foremost objectives of a FTA, especially a FTA 
involved developing countries, are so far still trade liber-
alization and therefore the trade impacts of a FTA have 
been key attention of both government and enterprises in 
the developing countries.
Trade impacts of a FTA have widely been accepted 
among scholars to include static and dynamic effects. 
Analysis of static impacts is often based on the theory 
of customs union and influenced by Viner (1950), who 
provided a conceptual framework for studying the trade 
effects of a FTA. Since Viner’s work, most of the other 
succeeding papers typically those by Cline (1978), Krue-
ger (1995), Panagariya and Findlay (1994), Panagariya 
and Krishna (2002), Katsioloudes and Hadjidakis (2007) 
and Dominick (2007) also agreed that analysis of the 
static impact of a customs union can be fully extended to 
analyze static impact of a FTA. As pointed out by Viner 
(1950), the static impact is measured by trade creation 
and trade diversion and therefore, the welfare impacts a 
FTA is ambiguous, depending on whether trade diversion 
or trade creation overwhelms.
According to Viner (1950), Katsioloudes and Hadjida-
kis (2007), Nguyen (2011), Hoang et  al. (2005), Plum-
mer et  al. (2010), Dominick (2007) and Negais (2009), 
trade creation occurs when domestic production in a 
FTA member is replaced by lower-cost production from 
another FTA member as a result of trade liberalization. 
In other words, there is a shift from the consumption 
of higher-price domestic products to lower-price prod-
ucts of other FTA members. The formation of a creation 
FTA therefore promotes trade between member states, 
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improves the efficient allocation of resources and cre-
ates a greater specialization in producing comparative 
advantage goods. As a result, a creation FTA leads to the 
increase in consumer surplus and finally the welfare of 
member nations.
On the contrary, a FTA can divert trade flows due to 
its nature of discrimination between member nations 
and non-member nations. As tariff and non-tariff bar-
riers are removed only within the FTA members, a 
FTA can make member nations divert imports from 
non-member nations into the member nations simply 
because the member countries enjoy preferential tariffs. 
On that ground, trade diversion occurs, worsening global 
resource allocation and shifting production away from 
comparative advantage. Therefore, a trade-diverting FTA 
leads to both trade creation and trade diversion, and can 
improve or worsen the welfare of members depending on 
the relative strength of these two opposing forces (Viner 
1950; Dominick 2007; Katsioloudes and Hadjidakis 2007; 
Plummer et  al. 2010; Nguyen 2011; Hoang et  al. 2005; 
Negais 2009).
Besides the static effects, FTAs also bring about 
dynamic effects that take a longer time to be exposed in 
the economy but tend to continue generating benefits 
overtime even after the withdraw of a country from a 
FTA. The impact of FTAs on exploitation of economies 
of scale was confirmed by Evans et  al. (2007), Katsiol-
oudes and Hadjidakis (2007), Eicher et  al. (2009) and 
Tran (2002). Furthermore, FTAs lead to other benefits 
such as promotion of specialization, competition, tech-
nology transfer, and improvement of efficiency as well as 
growth rate of the whole economy (Plummer et al. 2010; 
Eicher et al. 2009; Jha et al. 2010). With the development 
of new-generation FTAs, they also promote cooperation 
in other areas such as property right protection, job crea-
tion and sustainable development. Creating opportuni-
ties for member nations, especially developing countries, 
in reforming and harmonizing trade policies is another 
benefit that member nations seek for when joining a FTA 
(Katsioloudes and Hadjidakis 2007).
However, there are some challenges from FTAs that 
member nations should take into consideration. Firstly, 
from the social welfare perspective, a FTA is only the 
second best choice after multilateral liberalization due to 
its nature of discrimination against countries outside the 
FTA. Secondly, a FTA causes trade diversion and there-
fore can reduce welfare. Thirdly, participation in multiple 
FTAs at the same time leads to noodle bowl effects with 
complicated and overlapping rules of origin, and regula-
tory framework inconsistency, creating difficulties for 
governments in complying with FTAs and transaction 
costs for enterprises (Bui 2010; Multilateral Economic 
Cooperation Department 2009).
Literature review on the impact of the EVFTA on Vietnam’s 
economy and trade
While the previous literature on the impact of FTAs, 
such as the ASEAN Trade in Goods Agreement 
(ATIGA), ASEAN-China FTA (ACFTA), Vietnam-Korea 
FTA (VKFTA), ASEAN-Japan comprehensive economic 
partnership agreement (AJEAP), ASEAN-Australia-New 
Zealand FTA (AANZFTA) and the TPP, on Vietnam’s 
economy in general and on trade in particular is inten-
sive, there is a lack of papers focusing on trade impacts 
of the EVFTA. The EVFTA covers a big market with 28 
partners, but most of the special attention by Vietnam’s 
enterprises and researchers has currently been prone to 
the TPP. One of the reasons for this situation is the lack 
of information and research on the impact of the EVFTA 
on Vietnam, especially sector trade impacts, while those 
on TPP are prevalent. Typical previous papers examin-
ing the impact of the EVFTA on Vietnam include Philip 
et al. (2011), Baker et al. (2014), Nguyen (2014a), Brauer 
et al. (2014) and Vu (2015). The first four papers focused 
on analyzing the effects of tariff reduction under the 
EVFTA on the whole Vietnam’s economy such as state 
budget, domestic demand, price, saving, investment, 
trade, employment and economic growth, and pointed 
out opportunities and challenges for Vietnam while Vu 
(2015) used trade indicators such as Revealed Compara-
tive Advantage, Export Specialization and Trade Inten-
sity to anticipate the potential benefits and losses of the 
EVFTA. Philip et al. (2011) and Baker et al. (2014) using 
the computable general equilibrium (CGE) also tried to 
estimate changes in Vietnam’s imports from EU in several 
sectors such as rice, garments, sugar, electronics, machin-
ery, chemicals, transport and communication. Nguyen 
(2014a) adopted the gravity model to estimate changes 
in overall trade flows between two nations. Philip et  al. 
(2011), Baker et al. (2014) and Nguyen (2014a) provided 
qualitative analysis of current development of some sec-
tors such as automotive, electronics, garments, furniture, 
coffee and fisheries in the context of upcoming EVFTA. 
However, all of the above studies examined the impact 
of the EVFTA without taking into consideration of Viet-
nam’s integration into other FTAs and so far there is vir-
tually no research investigating impacts of the EVFTA on 
Vietnam’s imports of pharmaceuticals.
Recent years have seen a great deal of papers concern-
ing the development of Vietnam’s pharmaceutical indus-
try. Nguyen (2014b), and Nguyen and Le (2015) analyzed 
the performance, market demands, products, enterprises 
and the competitive environment of the overall industry 
and examined the performance of some major players in 
the market. VCBS (2014) and EVBN (2014) focused its 
analysis on main features of Vietnam’s medicines market 
such as prices, types of medicines, distribution system, 
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price management, materials and legal policies while 
Hoang (2014) tried to position Vietnam’s pharmaceuti-
cal industry in the world pharmaceutical map. All of the 
above authors agreed that Vietnam’s medicines industry 
is in the early state of development with small and low-
competitive domestic firms, low investment, loose price 
management and intellectual property protection, and 
inadequate policies and mechanism for development of 
the sector. In addition, Vietnam’s pharmaceutical sector 
has been over-reliant on imported material inputs and 
pharmaceuticals (Nguyen 2014b), and overwhelmed by 
foreign companies in patent and specialty drug segments 
(EVBN 2014; VCBS 2014; Hoang 2014). Vietnam’s phar-
maceutical enterprises have mainly produced generic 
drugs at low-value and with limited types of products 
(Maybank KimEng 2015; Nguyen 2014b; Vinapharm 
2013). The authors, however, recognized the potentials 
for future development of the sector because of high 
demand, increasing health care expenditure (EVBN 2014; 
BMI 2016; HK 2014), higher access to the world medicine 
market (Vu 2014) and healthcare education improvement 
(Nguyen 2014b). One common feature of the above-
mentioned papers is that although they were relatively 
successful at describing the current status and pointing 
out problems of Vietnam’s pharmaceutical sector, they 
ignored describing the aspects of imports and exports 
whereas Vietnam has largely reliant on imported medi-
cines. Instead, imports and exports of Vietnam’s phar-
maceuticals have unsystematically updated and analyzed 
just through short articles such as those written by Le 
(2015), Nguyen (2015), Quoc (2009), The (2015a) and The 
(2015b). The survey of last literature therefore shows that 
there is a lack of studies on Vietnam’s imports of pharma-
ceuticals at 6-digit level of Harmonized System (HS) and 
there is no study on the impact of the EVFTA on Viet-
nam’s pharmaceutical imports at disaggregated level.
In summary, review of the past literature reveals some 
important research gaps. Firstly, while the impact of FTAs 
including the TPP on Vietnam’s economy is prevalently 
investigated in the previous studies, the impact of the 
EVFTA has been ignored. Secondly, the previous studies 
related to the EVFTA focused its analysis on the impact 
on the whole economy rather than trade impacts. Thirdly, 
there is a lack of study estimating comprehensively trade 
impact of the EVFTA by sector at disaggregated level. 
Fourthly, the previous literature estimated impacts of the 
EVFTA in isolation with other FTAs of Vietnam. Finally 
but most importantly, there is so far virtually no study 
quantifying impacts of the EVFTA on Vietnam’s import 
of pharmaceuticals from the EU. This paper therefore 
contributes to the past literature by analyzing ex-ante 
trade impacts of tariff elimination commitments under 
the EVFTA on Vietnam’s import of pharmaceuticals from 
the EU at disaggregated level of HS 6 digits, taking into 
consideration of Vietnam’s integration in this sector with 
the ASEAN + 3 and TPP countries.
An overview of Vietnam’s pharmaceutical imports 
from the EU
Pharmaceutical imports of Vietnam from the EU have 
a tendency to grow steadily during the period 2001–
2014 despite of the global financial crisis as well as the 
economic instability of the EU in debt crisis. In 2014, 
Vietnams’ pharmaceutical imports reached USD 1,108 
million, increasing by more than 10 times from USD 102 
million in 2001 (Fig.  1). This upward trend originated 
mainly from the increasing healthcare expenditure of 
Vietnam and strengthened trade relationships between 
Vietnam and the EU, notably the signing of the EU—Viet-
nam Partnership and Cooperation Agreement in 2012 
and the negotiations of the EVFTA from 2012.
In the period 2001–2014, the EU has consistently the 
biggest pharmaceutical import market of Vietnam with 
an increasing proportion (Fig.  1). In 2001, 30.15  % of 
Vietnam’s pharmaceutical imports came from the EU 
but in 2013 and 2014, this share increased to 48.82 and 
50.98  % respectively. Besides the EU, other big partners 
Vietnam has imported medicines from include India, 
South Korea, Thailand and China with the proportions of 
around 12.4, 7.7, 3.2 and 2.8 % in 2014, respectively (ITC 
2016). Pharmaceuticals are also the important imported 
commodity of Vietnam from the EU, ranking second 
after machinery and accounting for 12.5  % of Vietnam’s 
total imports from the EU in 2014.
In the past three years, Vietnam’s pharmaceuti-
cal imports from the EU also grew stronger than its 
imports from the rest of the world (Fig. 2), contributing 
to a strong increase in the EU’s market share in Vietnam. 
Besides, since 2005, the growth rates of the EU’s phar-
maceutical exports to the world were always lower than 
that of Vietnam’s pharmaceutical imports from the EU, 
except in 2013. The increasing tendency in value and 
proportion, and high growth rate of Vietnam’s medicines 
imports from the EU show the growing dependence of 
Vietnam on the EU market. Therefore, when the EVFTA 
comes into effect, requiring Vietnam to remove tariffs 
for medicines imported from the EU, it will undeniably 
affect Vietnam’s medicines imports as well as the domes-
tic market.
From 2009 up to 2014, among the EU nations, France, 
Germany, Italy, the United Kingdom (UK), Belgium, and 
Ireland were Vietnam’s biggest pharmaceutical import 
markets (Additional file  1), which accounted for more 
than 73  % of Vietnam’s total pharmaceutical imports 
from the EU in 2014 (Fig. 3). Before 2009, besides these 
countries, Hungary and the Netherlands were also two 
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major pharmaceutical sources for Vietnam. Vietnam 
virtually did not import from Estonia, Croatia, Luxem-
bourg, Slovakia, and Latvia and started to import from 
Finland, Malta, Czech Republic and Lithuania several 
years ago. Therefore, there is a big disparity in Vietnam’s 
pharmaceutical imports by the EU nation, showing that 
the country heavily depends on some key EU’s markets.
Concerning the import pattern by group of product, 
Vietnam imported from the EU “medicaments mixtures 
in dosage” (HS 3004) the most. HS 3004 import value 
rose continuously over the years from nearly USD 94 
million in 2001 to USD 954.17 million in 2014 (Addi-
tional file  2). Although the share of HS 3004 witnessed 
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Growth rate of EU's pharmaceutical exports to the world
Fig. 2 The growth rate of Vietnam and the EU’s pharmaceutical imports and exports, 2002-2014 (Unit: %). Source: Author’s calculations from ITC 
(2016)
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at a high level to reach 86.10 % of total Vietnam’s phar-
maceutical imports from the EU and 51.02  % of total 
Vietnam’s pharmaceutical imports from the world at the 
end of the period. In HS 3004 group, the biggest medi-
cines imported from the EU were “medicaments nes” (HS 
300490) such as analgesics, fever relief, anesthetics, anti-
HIV, anti cancer, Parkinson, and cardiovascular medi-
cines; followed by “antibiotics not containing penicillin, 
ampicillin, and amoxicillin” (HS 300420), “ antibiotics 
containing penicillin, ampicillin, and amoxicillin “ (HS 
300410), and “hormones medicines” (HS 300439).
Ranking second is “human and animal blood, antisera, 
vaccines, toxins and micro-organism culture” (HS 3002), 
whose import values soared by 16 times from USD 5.61 
million in 2001 to USD 89.88 million in 2014 (Addi-
tional file  2). Since 2009, Vietnam’s imports of HS 3002 
has sharply increased to reach the share of 8.11 % of the 
total value of Vietnam’s pharmaceutical imports from the 
EU, accounting for more than 52 % of total value of Viet-
nam’s HS 3002 imports from the world in 2014. For this 
group, the biggest products imported from the EU were 
“vaccines for human use” (HS 300220) and “vaccines for 
veterinary use” (HS 300230).
Vietnam also imported from the EU a small amount 
of “medicament mixtures not in dosage” (HS 3003) and 
“pharmaceutical goods” (HS 3006) with the correspond-
ing import turnovers of around USD 30.35 million and 
USD 31.48 million in 2014 (Additional file 2), accounting 
for only 2.74 and 2.84 % of total pharmaceutical imports 
of Vietnam from the EU. However, in comparison 
with overall imports of Vietnam from the world, more 
than 52.41 and 63.84  % of Vietnam’s HS 3003 and HS 
3006 imports were from the EU. For HS 3006, Vietnam 
imported from the EU “opacifying preparation for x-ray 
and diagnostic reagents “(HS 300630) the most while 
“medicaments nes, formulated, in bulk” (HS 300390) was 
the biggest imported product in HS 3003.
Two remaining groups namely “dressing packaged 
for medical use” (HS 3005), and “glands and extracts, 
secretions for organotherapeutic uses, and heparin and 
its salts” (HS 3001) took small proportions of 0.20 and 
0.01  % of Vietnam’s total drug imports from the EU, 
respectively. It is because most of the products in HS 
3005 can be produced by the domestic pharmaceutical 
companies. In addition, production of HS 3005 drugs 
does not require high technology, thus, Vietnam can 
import them from non-EU countries at lower prices such 
as Thailand and China. Nearly 71.75 % of Vietnam’s HS 
3005 imports were from these two countries while the 
share of imports from the EU accounted for only 9.38 % 
in 2014. For HS 3005 group, Vietnam imported from the 
EU “dressings and other articles having an adhesive layer” 
(HS 300510) the most.
Imports, preservation and utilization for therapy of HS 
3001 products, especially glands and extracts, require 
high technology and costs. In the context of the low-tech 
pharmaceutical domestic sector and low supply of these 
products in the world, Vietnam has therefore imported 
little glands and extracts from the world, including the 
EU. Instead, for HS 3001, Vietnam imported most from 
EU “heparin and its salts” (HS 300190). In 2014, Viet-





















Fig. 3 Pattern of Vietnam’s pharmaceutical imports by the EU partner in 2014 (Unit:  %). Source: Author’s calculations from ITC (2016)
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only 0.01 % of its total pharmaceutical imports from the 
EU and over 9.91 % of Vietnam’s HS 3001 imports from 
the world.
Vietnam’s tariff reduction commitments on pharmaceutical 
imports from the EU
Vietnam imposed a relatively stable and low tariff on 
pharmaceuticals imported from the EU. From 2012 to 
2014, the pharmaceutical tariff lines at 0 % nearly stayed 
the same, accounting for 62.63 and 63.64 % of total tariff 
lines respectively and the average tariff rate remained 
unchanged at 2.26 % despite slight changes in tariff rates 
of HS 3004 and HS 3005 (see Table  1 at the end of the 
text file). In general, Vietnam did not impose tariff on HS 
3001 and HS 3002 while the rate on HS 3005 were at the 
highest level, increasing from 7 % in 2012 to 8 % in 2014.1 
The remaining three groups namely HS 3003, HS 3004, 
and HS 3006 were protected with the tariff rates of 2.00, 
2.22 and 2.67 % in 2012. In 2014, tariff rates imposed on 
HS 3003 and HS 3006 stayed the same but those on HS 
3004 decreased minimally to 2.13 %.2
On 1st February 2016, the full text of the EVFTA has 
been made public for information purposes and will be 
subject to legal revision for ratification. According to 
Vietnam’s tariff schedule3 disclosed so far, pharmaceuti-
cal tariff reductions are categorized into four groups: A, 
B5, B7 and B10 with the basic tariff rate of the negotiated 
year 2012. Accordingly, 62.63 % of pharmaceutical tariff 
lines are under Schedule A, where tariff rates shall be 
eliminated immediately on the date the EVFTA enters 
into force (Table 1). It is noted that Schedule A includes 
the tariff lines that were already at 0  % rate in the base 
year 2012. 1.01  % of tariff lines falls into Schedule B5, 
where tariff rates shall be removed in six equal annual 
stages beginning on the date the EVFTA comes into 
force. A large proportion of tariff lines, which is 33.34 %, 
are categorized into Schedule B7 to remove tariff in eight 
equal annual stages and the rest of 2.02 % into Schedule 
B10 with eleven equal-annual-stage of tariff removal 
starting on the date the EVFTA comes into effect.
More detailed, Vietnam’s tariff on the EU’s pharmaceu-
ticals shall be eliminated in the 11th year from the date 
the EVFTA comes into force, cut from 2.26 % of the base 
year to 1.99 % in the first year, 0.61 % in the middle year 
1 All of the five tariff lines in HS 3005 increased from 7 to 8 % from 2012 to 
2014.
2 Reduction in the tariff rate imposed on HS 3004 was due to a decrease 
from 5 to 0 % imposed on HS 30045021. All of other tariff lines in HS 3004 
remained unchanged.




and 0  % in the 11th year (Table  2). All of the products 
at 6-digit HS in HS 3001 and HS 3002, five of six in HS 
3003, two of eight in HS 3004 and six of nine in HS 3006 
were already at 0 % tariff rate, therefore the tariff reduc-
tion load on Vietnam would be left on HS 3004, HS 3005 
and some products in HS 3006. 
This paper aims at assessing the effects of only tar-
iff reduction under the EVFTA on Vietnam’s imports of 
pharmaceuticals because of the following reasons.
Firstly, at the global level, in most of the studies quanti-
fying trade impacts of FTAs, assessment of tariff removal 
has been a necessity and considered the first-order effect 
before conducting any other assessment of non-tariff 
barriers, even though the impacts of non-tariff barriers 
might be higher. In fact, the committed tariff schedule is 
more transparent and predictable, therefore the impact 
results are easier to be quantified and more persua-
sive. The impacts of non-tariff barriers on the contrary 
are much more difficult to be predicted and quanti-
fied because non-tariff barriers are less stable, related 
to policies and regulations that could be adjusted by 
domestic laws, and not bounded as stringently as tariff 
barriers. Especially for pharmaceutical products which 
affect considerably human’s lives and health, the possibil-
ity of countries to adopt beyond the border policies and 
trade defence measures for the purpose of protecting the 
health of community is eligible in many cases. There-
fore, even though impacts of tariff removal might be not 
so high, this assessment is treated as the first persuasive 
start to understand quantified changes in imports from 
FTAs.
Secondly, at the country level, together with trade lib-
eralization trend, Vietnam’s tariff barriers are decreas-
ing but concerns on these barriers in negotiating and 
implementing FTAs remain high. It is because Vietnam’s 
capacity to develop, adopt and monitor the complicated 
non-tariff barriers is limited, resulting to the fact that 
Vietnam has generally relied on tariff barriers to protect 
domestic industries. In addition, impacts of tariff are 
generally realized more quickly and clearly than impacts 
of non-tariff barriers. Therefore, the foremost concern of 
Vietnam’s enterprises whenever Vietnam joins a FTA is 
when and how much tariff would reduce, and how tar-
iff reduction would affect imports (Nguyen 2014c). In 
responses to this context of Vietnam, assessment of tariff 
barriers should be the first consideration for understand-
ing impacts of the EVFTA.
Thirdly, at the industry level, pharmaceuticals are the 
second biggest imported products of Vietnam from the 
EU. Furthermore, although the overall tariff Vietnam has 
imposed on the EU’s medicines are relatively low, the 
highest rates have been imposed on types of medicines 
Vietnam can produce domestically (HS 3005 and HS 
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3006) and on those Vietnam has imported most from the 
EU (HS 3004). Therefore, even though the total effects 
of tariff removal on Vietnam’s pharmaceutical imports 
might not be high, the distribution of the effects is more 
important. Understanding the impacts of tariff removal 
accordingly would help the government and enter-
prises to figure out the most vulnerable pharmaceutical 
products and then design appropriate strategies to pre-
pare for the future EVFTA.
Fourthly, also at the industry level, because of the 
increasing role of pharmaceuticals in Vietnam-EU trade, 
there is a separate Annex for pharmaceutical products 
and medical devices in the EVFTA. According to this 
Annex, two parties commit the principles to conduct 
Table 2 Vietnam’s tariff reduction schedule on pharmaceuticals imported from the EU under the EVFTA at 6-digit HS (%) 
Source: Author’s calculations from Vietnam’s tariff schedule under the EVFTA
Tariff rates for the whole pharmaceutical sector at 2-digit HS are in bold
Tariff rates for six pharmaceutical groups at 4-digit HS are in bolditalics
HS Base year 1st year 2nd year 3rd year 4th year 5th year 6th year 7th year 8th year 9th year 10th year 11th year
30 2.26 1.99 1.71 1.44 1.16 0.89 0.61 0.34 0.08 0.05 0.03 0.00
3001 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300110 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300190 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
3002 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300210 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300220 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300230 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300290 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
3003 2.00 1.75 1.50 1.25 1.00 0.75 0.50 0.25 0.00 0.00 0.00 0.00
300310 5.33 4.67 4.00 3.33 2.67 2.00 1.33 0.67 0.00 0.00 0.00 0.00
300320 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300331 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300339 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300340 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300390 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
3004 2.22 1.94 1.66 1.38 1.09 0.81 0.53 0.27 0.00 0.00 0.00 0.00
300410 2.60 2.28 1.95 1.63 1.30 0.98 0.65 0.33 0.00 0.00 0.00 0.00
300420 2.50 2.19 1.88 1.56 1.25 0.94 0.63 0.31 0.00 0.00 0.00 0.00
300431 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300432 1.67 1.46 1.25 1.04 0.83 0.63 0.42 0.21 0.00 0.00 0.00 0.00
300439 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300440 1.88 1.64 1.41 1.17 0.94 0.70 0.47 0.23 0.00 0.00 0.00 0.00
300450 1.00 0.83 0.67 0.50 0.33 0.17 0.00 0.00 0.00 0.00 0.00 0.00
300490 2.59 2.26 1.94 1.62 1.29 0.97 0.65 0.32 0.00 0.00 0.00 0.00
3005 7.00 6.13 5.25 4.38 3.50 2.63 1.75 0.88 0.00 0.00 0.00 0.00
300510 7.00 6.13 5.25 4.38 3.50 2.63 1.75 0.88 0.00 0.00 0.00 0.00
300590 7.00 6.13 5.25 4.38 3.50 2.63 1.75 0.88 0.00 0.00 0.00 0.00
3006 2.67 2.40 2.13 1.86 1.59 1.32 1.05 0.78 0.51 0.34 0.17 0.00
300610 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300620 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300630 1.75 1.53 1.31 1.09 0.88 0.66 0.44 0.22 0.00 0.00 0.00 0.00
300640 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300650 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300660 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300670 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
300691 5.00 4.38 3.75 3.13 2.50 1.88 1.25 0.63 0.00 0.00 0.00 0.00
300692 14.00 12.73 11.45 10.18 8.91 7.64 6.36 5.09 3.82 2.55 1.27 0.00
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measures to facilitate bilateral pharmaceutical trade and 
the use of international standards, practices and guide-
lines as a basis for the technical regulations. Vietnam 
also agrees to allow the EU enterprises to participate into 
pharmaceutical bidding contracts and price negotiation, 
import pharmaceuticals and sell pharmaceuticals to dis-
tributors in Vietnam. These commitments would poten-
tially remove substantially the long-lasing barriers for 
the EU enterprises, bringing about significant advantages 
for them over other foreign pharmaceutical enterprises. 
However, with all the information disclosed so far, it is 
still not clear about when, how and to what extent Viet-
nam will remove these barriers for the EU. Therefore, up 
to now, there is not enough information to assess impacts 
of the above mentioned non-tariff barriers on Vietnam’s 
pharmaceutical imports but it is more appropriate to 
focus at first the impacts of tariff removal. In addition, 
it is worth noting that patents on pharmaceuticals are 
considered more important than in most other sectors. 
However, in context of the EVFTA commitments, Viet-
nam and the EU have not agreed on pharmaceutical pat-
ents, and Vietnam has not successful at demanding the 
EU to reduce protection duration for patent medicines. 
Therefore, up to now, assessment of the effects of patents 
on pharmaceuticals in Vietnam might not be relevant. 
Last but not least, it is quite complicated to assess the 
impacts of the non-tariff barriers at disaggregated level 
since these barriers tend to affect across the different 
types of pharmaceutical products. It is unlike the tariff 
removal that clearly affects each type of medicines dif-
ferently. Therefore, given the objectives of this paper to 
assess the impacts of the EVFTA at disaggregated level 
to understand the distribution effect of the EVFTA, it 
would be more appropriate to examine tariff removal as 
the first–order effect. The assessment of non-tariff bar-
riers should be conducted when there are more informa-
tion about how these barriers will be eliminated and how 




Staronova (2007) argued that impact assessment aims 
at providing scientific-based evidence for policy-making 
decision and can be conducted by two ways namely ex-
ante impact assessment and ex-post impact assessment. 
The former is adopted to evaluate the potential impacts 
of policy changes that will be completed in a given point 
of time in the future while the later is used for policy 
changes that are already finished. As Vietnam and the 
EU have just concluded negotiations of the EVFTA that 
is expected to come into effort in 2018 at the soonest 
(Henriksson 2016; Ministry of Industry and Trade 2016; 
Delegation of the European Union to Vietnam 2016), ex-
ante impact assessment is an appropriate choice for case 
of the EVFTA.
As stated by Kehoe and Kehoe (1994a), Mikic (2005), 
Plummer et  al. (2010), Karingi et  al. (2005a), and Philip 
et al. (2011), the ex-ante impact assessment of a FTA can 
be carried out by different methods but the most com-
mon ones include: (1) trade indicators; (2) the partial 
equilibrium through adoption of the SMART; and (3) the 
computable general equilibrium (CGE) through GTAP 
model (Global Trade Analysis Project). Each method can 
be used to evaluate specific aspects of impacts of a FTA 
and has its own advantages and disadvantages. Trade 
indicators are used to describe, evaluate and compare 
trade flows and pattern of a country overtime or across 
countries (Mikic 2005). As argued by Plummer et  al. 
(2010) and Vu (2015), these indicators do not merely pro-
vide information on the current status of trade but are 
helpful in diagnosing potential impacts of a FTA. How-
ever, this method fails to provide the exact figures on 
impact of a FTA on trade and welfare, therefore, it is only 
regarded to be a first step to assess the future impact of a 
FTA. Among the methods adopted to assess impacts of 
trade policy changes, GTAP is so far the most compre-
hensive way in quantifying impacts of a FTA on different 
aspects of an economy such as GDP, trade, employment, 
investment, savings, price, and environment (Kehoe 
and Kehoe 1994b) because it stresses the interactions 
among sectors and markets (Nguyen 2014a). However, 
this method is quite complicated, requiring a wide range 
of data of all involved countries at both macroeconomic 
and industry level. In addition, as a CGE analysis, GTAP 
model also has its own disadvantages because it is con-
structed on ground of a series of complicated constraints 
and heavily depends on equilibrium conditions (Cal-
laghan 2009; Cassing et  al. 2010; Nguyen 2014a). More 
important, CGE cannot handle disaggregated data while 
a partial equilibrium model like the SMART allows eval-
uating impacts of a FTA at a much disaggregated product 
level (Admed 2010). The SMART also helps overcome 
the disadvantage of trade indicators approach in quanti-
fying trade impacts of a FTA. One special advantage of 
the SMART model is that it allows quantifying impacts 
of tariff policy changes in a single market on trade flows, 
tariff revenue, trade creation effect, trade diversion effect, 
and social welfare of a nation detailed at HS 6-digit prod-
ucts (Cheong 2010; Admed 2010; Othieno and Shinyekwa 
2011; Choudhry et al. 2013). Inference from results of the 
SMART simulation can also be good implications for 
both governments and enterprises in a given industry to 
prepare themselves for trade liberalization under a FTA. 
The appropriate selection of a research method should be 
based mainly on the objectives of the study. As this paper 
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aims at estimating impacts of the EVFTA on Vietnam’s 
imports of pharmaceuticals at detailed level of 6-digit 
HS, the partial equilibrium through the SMART model 
therefore is the most suitable choice for this paper. How-
ever, it is noted that as a partial equilibrium model, the 
SMART also has it own limitations, by which the biggest 
one is to ignore economic interactions between differ-
ent sectors in an economy. The model also neglects con-
straints on resources such as labor, land and capital, and 
movement of resources between sectors in an economy 
(Karingi et al. 2005a). Finally, the model does not return 
results on the effects on domestic production, which may 
be of interests to policy makers (Plummer et al. 2010).
Using the SMART model to analyze the future impact 
of a FTA is increasingly common due to the useful-
ness of this approach in assessing trade impacts at dis-
aggregated level to provide better implications for 
governments and enterprises. For example, Othieno and 
Shinyekwa (2011) used this model to evaluate the future 
effects of the East African Community Customs Union 
on Uganda’s trade, tariff revenue and social welfare in 
sensitive products. With the objectives of assessing the 
likely economic and welfare impacts of the EU Partner-
ship Agreement with the African countries at product 
level, Karingi et  al. (2005a) and Karingi et  al. (2005b) 
both applied the SMART model. Karingi et  al. (2005a) 
used this model for the case of the EU-Africa Economic 
Partnership Agreement and Karingi et al. (2005b) for the 
EU-ECOWAS (Economic Community of West African 
States) Economic Partnership Agreement. Adopting the 
SMART model to stimulate the likely trade creation and 
diversion effects of the India-Sri Lanka FTA in three sec-
tors including textiles, base metal and machinery equip-
ment, Choudhry et  al. (2013) saw a significantly higher 
trade creation than trade diversion and pointed out some 
products that seem to be benefited most for India from 
the agreement. Veeramani and Saini (2010) by using the 
SMART model found out that the ASEAN-India Pref-
erential Trade Agreement led to a significant increase 
in India’s imports of coffee, tea and pepper from the 
ASEAN countries and the trade creation dominated over 
trade diversion.
In Vietnam, the number of studies adopting the 
SMART model for ex-ante impact assessment is still very 
limited. This partial equilibrium model was initiated to be 
used from Cassing et al. (2010), followed by Philip et al. 
(2011), Baker et  al. (2014) and the most recent study of 
Tu and Le (2015). Cassing et al. (2010) used the SMART 
model to assess the future impacts of ASEAN  +  FTAs 
on Vietnam’s trade in some products such as footwear, 
fisheries, vegetable, electronics, cars, furniture and cof-
fee while Tu and Le (2015) examined the likely impacts 
of Regional Comprehensive Economic Partnership 
Agreement on Vietnam’s trade at the disaggregated level 
of 6-digit HS. Aiming at assessing the potential impacts 
of the EVFTA on Vietnam’s trade, Philip et al. (2011) and 
Baker et  al. (2014) made use of the SMART and CGE 
model. Philip et  al. (2011) focused on Vietnam’s export 
of garments and footwear whereas Baker et  al. (2014) 
extended the analysis to a wide range of products and 
found out that footwear and garments would receive the 
greatest gain from tariff liberalization under the EVFTA.
The objective of this paper is to assess ex-ante impact 
of the EVFTA on Vietnam’s pharmaceutical imports from 
the EU at 6-digit HS and decompose the total import 
changes into trade diversion and trade creation. From the 
past literature on advantages and disadvantages of differ-
ent ex-ante impact assessment methods and the review 
of last studies adopting the SMART model, this model is 
proved to be an appropriate and useful methodology for 
this paper given its objectives.
Data
The partial equilibrium SMART model and its simula-
tion tool are part of the world integrated trade solution 
(WITS) database and software developed by the World 
Bank in conjunction with the United Nation Conference 
on Trade and Development. (UNCTAD) The SMART 
simulation requires data on trade values and tariffs faced 
by each exporting partner. In this paper, import values 
of Vietnam with the EU and the rest of the world were 
extracted from UN’s COMTRADE (common format 
for transient data exchange) and Trade Map database. 
The Most Favoured Nation (MFN) import tariff rates 
imposed by Vietnam on each partner were taken from 
UNCTAD’s TRAINS (trade analysis and information sys-
tem), the WTO’s IDB (Integrated Data Base) and Minis-
try of Finance of Vietnam.
In addition, SMART requires three following parameters 
as inputs for the model: (1) import demand elasticity; (2) 
import substitution elasticity and (3) export supply elastic-
ity. These elasticity come from the fact that the SMART 
model is developed based on the economic theories 
related to import demand and export supply with three 
important assumptions: (1) the Armington assumption of 
import demand side, (2) two-stage optimization process 
and (3) assumption of infinite export supply elasticity.
The import demand in the model is constructed based 
on the Armington assumption that commodities are dif-
ferentiated by their origin countries. This assumption 
implies that there is an imperfect substitution between 
import sources and therefore, import demand does not 
completely shift to a FTA member although the FTA 
provides trade preferential. The SMART model also sup-
poses that consumers make decisions on demand based 
on two-stage optimization process, which is related to 
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the allocation of their expenditures by commodity and 
by import source (Amjadi et al. 2011; Admed 2010; Laird 
and Yeats 1986). At the first stage, consumers decide on 
how much to spend totally for imported goods on basis 
of import demand elasticity, whose values in the SMART 
model have been empirically estimated for each coun-
try and every HS 6-digt product based on Stern et  al. 
(1976). At the next stage, they allocate expenditure among 
imported goods from different import sources based on 
their relative price. The change in allocation of expendi-
tures by imported sources when the relative price changes 
is known as import substitution elasticity, which is sup-
posed to be equal to 1.5 in the SMART model. For a given 
goods, different countries have to compete to export to 
an import market. The degree of responsiveness of the 
export supply to changes in the export price is given by 
the export supply elasticity. The SMART model assumes 
infinite export supply elasticity, implying that the export 
supply curves are flat and the world prices of each vari-
ety are exogenously given. Therefore, the export country 
can export as many as it can at a given world price. This is 
often called the price taker assumption, which is suitable 
for a small import country case. Under the assumption of 
infinite export supply elasticity, the SMART model allows 
estimating a quantity effect of a tariff reduction while the 
price effect is always equal to zero. By default, the SMART 
model uses 99 for an infinite elasticity for all products and 
partners (Amjadi et al. 2011; Veeramani and Saini 2010).
The Armington assumption of imperfect substitution 
is widely accepted in the previous studies applying the 
SMART model. This assumption is accordingly rational 
in the case of Vietnam and the EU because the pharma-
ceuticals of the EU are differentiated from those of the 
rest of the world and the EVFTA will not shift completely 
Vietnam’s pharmaceutical imports from the rest of the 
world to the EU. In addition, Vietnam is a small pharma-
ceutical importer in the world in general and with the EU 
in particular; therefore, the assumption of infinite elastic-
ity embodied in the SMART model is also appropriate, 
showing that the increase in Vietnam’s pharmaceutical 
imports will not affect price in the EU. So, the value of 99 
for export supply elasticity was adopted in this paper. The 
import substitution elasticity was set at 1.5 as specified 
in the SMART model because it is appropriate for indus-
trial products as suggested by (Amjadi et  al. 2011). The 
import demand elasticity detailed at 6-digit HS defaulted 
in the SMART were also applied in this paper because of 
its usefulness and accuracy at disaggregated level. In fact, 
using these elasticity parameters of the SMART model is 
a common approach used in the previous studies such as 
Cassing et al. (2010), Othieno and Shinyekwa (2011), Veer-
amani and Saini (2010), Karingi et  al. (2005a, b), Philip 
et al. (2011), Baker et al. (2014), and Tu and Le (2015).
Finally, this paper adopted the HS classification, by 
which pharmaceuticals are divided into 6 groups of 
products namely: (1) HS 3001—glands and extracts, 
secretions for organotherapeutic uses, and heparin and 
its salts; (2) HS 3002—human and animal blood, anti-
sera, vaccines, toxins and micro-organism culture; (3) 
HS 3003—medicament mixtures not in dosage; (4) HS 
3004—medicaments mixtures in dosage; (5) HS 3005—
dressing packaged for medical use and (6) HS 3006—
pharmaceutical goods.
Scenarios
Two scenarios were constructed based on Vietnam’s 
commitments of tariff reduction on pharmaceuticals 
under the EVFTA as well as the current pace of Vietnam’s 
integration in this sector with the rest of the world.
Vietnam and the EU signed the Declaration on the con-
clusion of the negotiations of the EVFTA in December 
2015 and are conducting legal reviews to ratify this 
Agreement. It is expected that the EVFTA will enter into 
force in 2018. Based on this expectation and experience 
from the EU-Singapore FTA,4 the paper assumes that the 
EVFTA will come into force in 2018 and therefore Viet-
nam will complete to eliminate tariffs on pharmaceuticals 
from the EU by 2028. The base year for two scenarios is 
2014.
•  Scenario 1: Vietnam eliminates tariff on pharmaceu-
ticals imported from the EU as scheduled from 2018 
to 2028. Other integration process of Vietnam in the 
pharmaceutical sector with the rest of the world is not 
taken into consideration.
This scenario aims at examining the impact of the 
EVFTA on Vietnam’s pharmaceutical imports from the 
EU in isolation with integration of Vietnam in other 
FTAs to identify more clearly how the EVFTA will affect 
Vietnam.
•  Scenario 2: Vietnam eliminates tariff on pharmaceuti-
cals imported from the EU as scheduled from 2018 to 
2028. In addition, Vietnam will also remove pharma-
ceuticals tariffs for TPP nations from 2018 to 2028 and 
for ASEAN + 3 (ASEAN and its three partners includ-
ing China, South Korea and Japan) by 2028.
4 The EU and Singapore launched negotiation of the EU-Singapore FTA in 
March 2010. The Goods and Services Agreement was concluded in 2012 
and the Investment Chapter in 2014. However, it is expected that two par-
ties will ratify the Agreement after 2016. Thus, it takes around 3 years for 
an FTA with the EU to come into effort from the date of conclusion of the 
negotiation.
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The TPP concluded recently requires Vietnam to open 
up the pharmaceutical market for the member countries. 
Up to now, like the EVFTA, the TPP is also expected to 
come into force in 2018 (WTO Center 2016; Nguyen 
2016; Damodaran 2016). According to TPP’s full text that 
was already made public, the total duration for Vietnam 
to remove tariff for this sector would be 10 years, which 
is the same as that of the EVFTA.5 Therefore, the second 
scenario assumes that both the EVFTA and TPP will 
come into force in 2018 and Vietnam will finish removing 
tariffs for pharmaceuticals imported from the EU and 
TPP in 2028.
The commitments of Vietnam in the EVFTA and TPP 
in the pharmaceutical sectors are higher than that in 
other FTAs between Vietnam and ASEAN +  3 nations. 
While all tariff lines are eliminated under the EVFTA 
and TPP after ten years, Vietnam made the same com-
mitment to reserve a peak tariff of 14  % for HS 300692 
(waste pharmaceuticals) under ATIGA, ACFTA, VKFTA 
and the Vietnam-Japan Economic Partnership Agree-
ment (VJEPA) (Ministry of Fanance 2014a, b; WTO 
Center 2013; Ministry of Industry and Trade 2014; WTO 
Center 2015). Vietnam also keeps positive tariff rates of 
0–5 % for some tariff lines such as HS 30049099 in VJEPA 
and HS 30041016 in VKFTA. Therefore, this scenario 
optimistically assumes that under pressure of integra-
tion, ASEAN + 3 nations would try to keep up with the 
pace of liberalization in the TPP and EVFTA by removing 
pharmaceutical tariffs within the region.
Totally, scenario 2 assumed that the pharmaceutical 
tariffs Vietnam imposes on the EU, TPP and ASEAN + 3 
are all 0  % in 2028. This scenario included 41 nations 
(Additional file  3), which provided more than 77.8  % 
of Vietnam’s imports of pharmaceuticals in 2014 (ITC 
2016). Therefore, the scenario is expected to bring about 
a comprehensive and precise picture of the changes in 
Vietnam’s imports of pharmaceuticals from the EU when 
Vietnam integrates at the highest level in its existing key 
FTAs.
Results
Impacts of the EVFTA on overall changes in Vietnam’s 
pharmaceutical imports from the EU
The simulation results show that Vietnam’s pharmaceuti-
cal imports from the EU would increase in both scenarios 
(Table  3) because of two main reasons. Firstly, the EU’s 
pharmaceuticals would be cheaper than before when 
Vietnam removes tariffs under the EVFTA. Secondly, the 
5 Tariff schedule of Vietnam under the TPP can be seen at https://ustr.gov/
sites/default/files/TPP-Final-Text-Viet-Nam-Tariff-Elimination-Schedule.
pdf.
EU’s pharmaceuticals would be less expensive than phar-
maceuticals from the rest of the world or in other worlds 
the relative price of the EU’s pharmaceuticals would 
reduce.
However, the tariff elimination would be likely not to 
affect considerably Vietnam’s imports of medicines from 
the EU because of relatively low level of initial tariff rates. 
In the first scenario when Vietnam only dismantles tar-
iffs for the EU, Vietnam’s pharmaceutical imports from 
the EU would increase by 3.08 % compared to the initial 
level of the base year, equivalent to USD 34.11 million 
(Table  3). These figures for scenario 2 would be 2.78  % 
and USD 30.74 million respectively.
The increase in Vietnam’s medicines imports from the 
EU would be 9.8 % lower in scenario 2 than in scenario 
1. It is because when Vietnam tries to integrate with not 
only the EU but also the TPP and ASEAN +  3 nations 
in scenario 2, Vietnam would shift a part of its phar-
maceutical imports previously from the EU to TPP and 
ASEAN + 3. However, the reduction of 9.8 % implies that 
the deeper integration of Vietnam with two other groups 
would not result in a big decrease in Vietnam’s imports 
from the EU. Therefore, the EU would still be leading 
pharmaceutical market of Vietnam in the coming years.
Impacts of the EVFTA by the EU country
There would be a significant difference in import value 
changes by partner in both scenarios. France would be 
the nation that Vietnam increases imports most, followed 
by Germany, the UK and Italy (Table 4). These four mar-
kets might account for around 69 % of additional imports 
of Vietnam from the EU in both scenarios. Belgium, Aus-
tria, Spain, Ireland and Sweden would together represent 
19  % of Vietnam’s increased imports from the EU. The 
concentration of import increases in these countries 
could be mainly explained by their big initial trade with 
Vietnam. Another explanation might be the high produc-
tion and export levels of pharmaceutical sectors wit-
nessed in these countries for years (EFPIA 2014; ITC 
Table 3 Overall changes in  Vietnam’s pharmaceutical 
imports from the EU in two scenarios Source: Author’s cal-
culations from SMART simulation results
Indicator Scenario 1 Scenario 2
Initial import value (‘000 USD) 1,108,164 1,108,164
Import value in 2028 (‘000 USD) 1,142,273 1,138,937
Total import changes (‘000 USD) 34,109 30,773
Trade creation (‘000 USD) 17,639 17,639
Trade diversion (‘000 USD) 16,470 13,134
Increase in imports (%) 3.08 2.78
Trade creation/total import changes (%) 51.71 57.32
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2016). Therefore, there world be a great deal of opportu-
nities for these countries to promote exports of medi-
cines to Vietnam when the EVFTA comes into effect. On 
the contrary, Lithuania and Luxembourg could not 
increase their exports to Vietnam. Increases in Vietnam’s 
imports would be very low for other EU countries, which 
have been small pharmaceutical sources for Vietnam.6
The growth rate of Vietnam’s pharmaceutical imports 
from France, Germany, the UK and Italy, which are also 
those who take up the biggest proportion of increases 
in Vietnam’s imports, would stay at the relatively high 
level of more than 3.2 % (Table 4). Some countries would 
have a potentially dynamic growth rate in exporting to 
6 Two countries namely Croatia and Estonia were not included in the model 
because of insufficient data. Therefore, estimations from SMART simu-
lations might be lower than the real changes. However, this difference is 
expected to be marginal as Croatia and Estonia were small pharmaceutical 
import markets of Vietnam.
Vietnam even though their initial trade values with Viet-
nam were not high such as Slovenia, Cyprus, Romania, 
Portugal and Greece. Pharmaceutical imports of Vietnam 
from Denmark, Czech Republic, Lithuania, Luxembourg 
and Netherland would growth at low level of below 1.5 % 
whereas from other countries of between 1.9 and 3.7 %.
Impacts of the EVFTA by pharmaceutical group
The simulation results show that there would be an une-
ven distribution of Vietnam’s increased imports from the 
EU by pharmaceutical group. In both scenarios, nearly 
98 % of increases in pharmaceutical imports of Vietnam 
from the EU would fall into HS 3004 (Table 5), reaching 
USD 33.2 million in scenario 1 and nearly USD 30 million 
in scenario 2. In comparison with scenario 1, Vietnam’s 
overall pharmaceutical imports from the EU decreases 
by USD 3.3 million in scenario 2, mainly because of the 
decrease in imports in this group of product. It implies 
Table 4 Changes in Vietnam’s pharmaceutical imports by the EU country Source: Author’s calculations from SMART simu-
lation results
No. Nation Scenario 1 Scenario 2









1 France 8474 24.84 3.24 7677 24.95 2.94
2 Germany 6615 19.39 3.37 5993 19.48 3.05
3 UK 4276 12.54 3.59 3798 12.34 3.19
4 Italy 4187 12.28 3.46 3771 12.25 3.11
5 Belgium 1544 4.53 2.34 1387 4.51 2.10
6 Austria 1439 4.22 3.66 1308 4.25 3.33
7 Spain 1352 3.96 3.19 1220 3.97 2.88
8 Ireland 1096 3.21 2.13 994 3.23 1.93
9 Sweden 1030 3.02 3.62 939 3.05 3.30
10 Poland 797 2.34 2.75 710 2.31 2.45
11 Hungary 771 2.26 1.88 706 2.29 1.72
12 Cyprus 676 1.98 3.93 599 1.95 3.48
13 Netherlands 494 1.45 1.34 448 1.46 1.22
14 Bulgaria 396 1.16 3.53 355 1.15 3.16
15 Romania 247 0.72 3.78 224 0.73 3.43
16 Portugal 236 0.69 3.72 214 0.69 3.38
17 Greece 217 0.64 3.71 197 0.64 3.37
18 Slovenia 164 0.48 4.55 145 0.47 4.02
19 Denmark 39 0.12 0.17 36 0.12 0.16
20 Finland 18 0.05 2.55 17 0.05 2.35
21 Malta 16 0.05 3.66 14 0.05 3.33
22 Czech 13 0.04 1.46 12 0.04 2.71
23 Latvia 6 0.02 3.66 5 0.02 3.33
24 Slovak 5 0.01 3.66 4 0.01 3.33
25 Lithuania 0 0.00 0.09 0 0.00 0.00
26 Luxembourg 0 0.00 0.00 0 0.00 0.00
Total 34,109 100.00 3.08 30,773 100 2.78
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that when Vietnam removes tariff for the EU, ASEAN + 3 
and TPP, Vietnam would shift substantially its imports 
of HS 3004 to the TPP and ASEAN +  3 nations. These 
results could be explained by the fact that HS 3004 has 
been the key import product of Vietnam from both 
ASEAN + 3 and TPP. According to the SMART simula-
tion results, Vietnam would import much more HS 3004 
from the US and Australia in scenario 2 in comparison 
with scenario 1 (Additional file 4).
The increase in Vietnam’s imports of HS 3005 from 
the EU would be not high in value but grows at a rocket 
rate of around 17 % in both scenarios (Table 5). This high 
growth rate results from the initial high tariff rates Viet-
nam imposed on HS 3005. In scenario 2 when Vietnam 
removes tariff for all three groups of countries, its imports 
of HS 3005 from the EU would witness a slight decrease of 
about 3.9 % compared with that of scenario 1 and Vietnam 
would substitute a small part of HS 3005 imports from the 
EU for imports from the US, Korea, and Japan (Additional 
file 4). One notable feature is that Vietnam in this scenario 
would reduce substantially imports of HS 3005 from Thai-
land and China, which have been two biggest destinations 
of Vietnam for HS 3005. This can be explained by the fact 
that ASEAN and China already received 0  % tariff rate 
for this group of product from 2018, before the year that 
EVFTA and TPP are expected to come into effect. There-
fore, when pharmaceuticals from the EU and TPP nations 
(excluding nations that are members of both ASEAN 
and TPP) are allowed to enter Vietnam at 0 % tariff rate, 
their prices relative to those of ASEAN and China nations 
would be lower than before, creating a price disadvantage 
for ASEAN and China in the Vietnamese market.
The increases in Vietnam’s HS 3006 imports from the 
EU would be modest in both value and growth rate in two 
scenarios (Table 5), equivalent to about USD 0.4 million 
at 1.2 % growth rate. However, Vietnam’s integration with 
the TPP and ASEAN + 3 nations would affect greater on 
Vietnam’s imports of HS 3006 than imports of HS 3005 
from the EU. In fact, Vietnam’s imports of HS 3006 from 
the EU in scenario 2 decrease by 12.5 % compared to sce-
nario 1 whereas this figure for HS 3005 is only 3.9 %. The 
US would be the new destination substituting substan-
tially the EU in Vietnam’s imports of HS 3006. Japan and 
Canada are other replacements for the EU but at a lower 
level (Additional file 4).
The tariff removal for HS 3003 would result in a negli-
gible increase in Vietnam’s imports of this group from the 
EU in both scenarios (Table 5). It is because HS 3003 has 
been a minor import commodity of Vietnam from the EU 
and been imposed the lowest tariff rate in comparison 
with other three tariff-imposed groups. In addition, there 
would be merely no change between scenario 1 and 2 in 
HS 3003 imports of Vietnam from the EU, implying that 
Vietnam’s integration with ASEAN +  3 and TPP would 
not affect its imports of HS 3003 from the EU. This comes 
from the fact that Vietnam has imported HS 3003 much 
lower from ASEAN +  3 and TPP nations than the EU, 
and almost all import tariff rates imposed on HS 3003 
from ASEAN + 3 and TPP were already at 0 %.
In both scenarios, Vietnam would not change imports 
of HS 3001 and HS 3002 from the EU because all of the 
tariff lines for these two groups were already at 0 % in the 
base year.
Impacts of the EVFTA by pharmaceutical product
The above analysis points out that there are three groups 
of pharmaceuticals that Vietnam should take into more 
careful consideration. They are HS 3004, which Vietnam 
would face with the highest increase in import values; HS 
3006, which might be the second biggest changed groups; 
and HS 3005 whose imports could grow at a dynamic 
rate. Therefore, the paper analyzes more deeply the 
changes in imports of these groups at product level, on 
that ground identifying the most vulnerable products for 
Vietnam in the process of integrating with the EU in the 
pharmaceutical sector.
Table 5 Changes in Vietnam’s pharmaceutical imports from the EU by group of product Source: Author’s calculation from 
SMART simulation results
Group of product Scenario 1 Scenario 2









HS 3001 0.00 0.00 0.00 0.00 0.00 0.00
HS 3002 0.00 0.00 0.00 0.00 0.00 0.00
HS 3003 36 0.11 0.12 36 0.12 0.12
HS 3004 33,262 97.52 3.49 29,995 97.47 3.14
HS 3005 380 1.11 17.01 365 1.19 16.35
HS 3006 431 1.26 1.37 377 1.22 1.20
Total 34,109 100.00 3.08 30,773 100.00 2.78
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Among HS 4004, Vietnam would increase imports of 
HS 300490 at the largest such as antiseptics; anesthet-
ics; painkiller; fever relief medicines; medicines contain-
ing acetylsalicylic, chlorpheniramine maleate, diclofenac 
and piroxicam; and especially specialty drugs (anti-can-
cer/HIV, diabetes and cardiovascular medicaments) that 
Vietnam so far could not produce. The increase in Viet-
nam’s imports of HS 300490 would take up of around 
76  % of total additional imports from the EU in both 
scenarios (Table 6). When Vietnam eliminates tariffs for 
all three groups of countries in scenario 2, the EU would 
lose a part of HS 300490′s market in Vietnam to the US 
and Australia.
Ranking second after HS 300490 in terms of the import 
increase would be HS 300420 (antibiotics not containing 
penicillin, ampicillin, and amoxicillin) and coming third 
would be HS 300410 (antibiotics containing penicillin, 
ampicillin, and amoxicillin). These two products together 
would account for about 20 % of total additional pharma-
ceutical imports of Vietnam from the EU in both scenar-
ios (Table 6). In scenario 2, integration of Vietnam with 
the TPP and ASEAN + 3 nations would result in a rela-
tively high reduction Vietnam’s imports of HS300410 and 
HS 300420 from the EU. Korea would be the key nation 
that replaces the EU’s pharmaceuticals in Vietnam for 
both HS 300410 and HS 300420, especially HS 300420. 
Thailand and China would be also other destinations for 
Vietnam to replace imports from the EU.
In both scenarios, HS 300432 (Adrenal cortex hor-
mone and its derivatives) and HS 300630 (Opacifying 
preparation for x-ray and diagnostic reagents) would 
incur a small increase of more than 1 % in total additional 
imports of Vietnam from the EU (Table 6). In compari-
son with scenario 1, tariff elimination for all groups of 
countries in scenario 2 would result in a small decrease 
in Vietnam’s import from the EU for HS 300432 but a 
relatively big decrease of 13.2 % for HS 300630. Vietnam 
would shift its imports of HS 300432 from the EU mainly 
to Canada and HS 300630 to the US.
Besides, Vietnam’ import of HS 300510 (Dressings 
and other articles having an adhesive layer) and HS 
300590 (Dressings and similar articles, impregnated or 
coated or packaged for medical use) would incur a sig-
nificant growth rate of between 16 and 17 % compared 
to the initial levels (Table 6). These products have been 
highly protected by Vietnam for a long time. Therefore, 
Table 6 Changes in Vietnam’s pharmaceutical imports from the EU by product Source: Author’s calculations from SMART 
simulation results
Product Scenario 1 Scenario 2









HS 3004 33,262 97.52 3.49 29,995 97.47 3.14
300410 2275 6.67 5.25 1979 6.43 4.57
300420 4826 14.15 4.16 4129 13.42 3.56
300431 0 0.00 0.00 0 0.00 0.00
300432 468 1.37 2.08 454 1.47 2.02
300439 0 0.00 0.00 0 0.00 0.00
300440 45 0.13 4.32 45 0.15 4.32
300450 0 0.00 0.00 0 0.00 0.00
300490 25,647 75.19 3.65 23,388 76.00 3.33
HS 3005 380 1.11 17.01 365.0 1.19 16.35
300510 204 0.60 16.90 193 0.63 16.00
300590 176 0.52 17.15 172 0.56 16.77
HS 3006 431 1.26 1.37 377 1.22 1.20
300610 0.0 0.00 0.00 0 0.00 0.00
300620 0.0 0.00 0.00 0 0.00 0.00
300630 408 1.20 2.11 354 1.15 1.83
300640 0.0 0.00 0.00 0 0.00 0.00
300650 0.0 0.00 0.00 0 0.00 0.00
300660 0.0 0.00 0.00 0 0.00 0.00
300670 0.0 0.00 0.00 0 0.00 0.00
300691 23 0.07 6.70 23 0.07 6.64
300692 0.1 0.00 11.28 0 0.00 11.28
Total 34,109 100.00 3.08 30,773 100.00 2.78
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the Vietnamese enterprise would face with higher com-
petition from the EU for these two products when the 
EVFTA comes into force. Comparison of the changes in 
Vietnam’s imports from the EU in two scenarios points 
out that the effort of Vietnam’s in removing pharma-
ceutical tariffs for ASEAN  +  3 and TPP would not 
affect considerably its imports of these two products 
from the EU.
Trade creation and diversion effect
When Vietnam dismantles tariffs for the EU, its imports 
from the EU would increase in both scenarios as dis-
cussed above and the total additional imports could be 
decomposed into two parts namely trade creation and 
trade diversion.
Under the tariff reduction from the EVFTA, the EU 
pharmaceuticals would become cheaper than before and 
the EU pharmaceutical imports therefore would replace 
high-cost domestic production. The increase of Vietnam’s 
imports from the EU in this case is called trade creation 
that would be unchanged across scenarios. Trade crea-
tion improves welfare as domestic resources are allocated 
more efficiently but creates competition for the domestic 
producers.
In addition, the EVFTA would lower the price of the EU 
pharmaceuticals relative to pharmaceuticals from other 
part of the world. The increase in Vietnam’s imports from 
the EU due to reduction of the EU’s pharmaceutical rela-
tive price is called trade diversion, which lowers welfare 
because the low-cost production from the rest of the word 
is replaced by less efficient FTA member and production is 
forced to shift away from the comparative advantage.
The simulation results show that trade creation effect 
would be higher than trade diversion effect in both sce-
narios, implying that the EVFTA would improve wel-
fares of Vietnam. When Vietnam removes tariff for only 
the EU, trade creation would account for 51.71 % of total 
trade effect (see Table 7 at the end of the text file). When 
the EU, ASEAN + 3 and TPP could export pharmaceuti-
cals to Vietnam at 0 % tariff rate, the difference between 
price of the EU’s pharmaceuticals and pharmaceuti-
cals from ASEAN + 3 and TPP would be narrowed and 
therefore lowering the trade diversion that Vietnam suf-
fers from. The share of trade creation in total trade effect 
of scenario 2 would increase to 57.32 % from 51.71 % in 
scenario 1 and all of the affected EU nations would have 
trade creation effect that is higher than trade diversion 
effect. However, despite the improvement in trade crea-
tion ratio, trade creation still could not dominate trade 
diversion, showing that the improvement of Vietnam’s 
welfare would be not so high.
Trade creation effect would be unevenly distributed 
among the EU member countries, by which most of 
trade creation belongs to France, Germany, the UK and 
Italy in both scenarios (Table  7). In addition, besides 
France and the UK, Slovenia, Czech Republic, Denmark 
and Ireland would also receive the above-average share 
of trade creation in total trade effect. Another point of 
interest is to identify the non-EU countries whose trade 
is being replaced by imports from the EU as a result of 
the EVFTA. When Vietnam only removes tariff for the 
EU in scenario 1, India would be the biggest losers, fol-
lowed by Korea, Switzerland and the US (Table 8). Viet-
nam’s imports of pharmaceuticals would also be diverted 
substantially from Thailand, China, Australia and Japan 
to the EU. In addition, among the top ten non-EU coun-
tries that would suffer from the largest extent of trade 
diversion, there would be seven nations that Vietnam at 
present have FTAs with including India, Korea, Thailand, 
China, Australia, Japan and Indonesia. It implies that 
the EVFTA potentially affects negatively on Vietnam’s 
integration with ASEAN + 3 in particular and the Asian 
region in general.
Discussion
From the above SMART simulation results, some follow-
ing important implications are drawn to support Vietnam 
to well prepare for the upcoming EVFTA in the pharma-
ceutical sector.
Firstly, the SMART simulation results show that in 
overall tariff removal for the EU’s medicines would not 
result in a significant increase in Vietnam’s imports 
from the EU, but Vietnam’s deeper integration with 
ASEAN + 3 and TPP would only affect slightly on Viet-
nam’s imports from the EU. In scenario 1, Vietnam’s 
imports of pharmaceuticals from the EU would increase 
by 3.08 % while this figure for scenario 2 would be 2.78 %. 
Therefore, impacts of the EVFTA on Vietnam’s imports 
of pharmaceuticals would be relatively stable regard-
less of efforts of Vietnam in integrating with the rest of 
the world. In other words, it would be expected that in 
the near future, the EU would be still the most impor-
tant and biggest source of pharmaceuticals for Vietnam. 
Therefore, both the Vietnamese government and phar-
maceutical enterprises, especially the enterprises should 
pay more attention to the EVFTA and its impacts on the 
pharmaceutical sector instead of focusing too much on 
the TPP and neglecting the EVFTA as so far.
Secondly, in both scenarios, there might be an une-
ven distribution in Vietnam’s import increases among 
the EU nations. Around 60  % of increase in Vietnam’s 
pharmaceutical imports would be concentrated most in 
France, followed by Germany, the UK and Italy. There-
fore, the paper argues that the biggest competition when 
the EVFTA comes into effect would come from France, 
Germany, the UK and Italy and this competition would 
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be long-lasting because the increased imports of Vietnam 
from these countries are high in terms of both value and 
growth rate. For this reason, the Vietnamese enterprises 
should put a high priority on understanding the leading 
pharmaceutical enterprises from these countries in terms 
of their products, quality, development trend and espe-
cially strategy to penetrate the Vietnamese market. From 
the Vietnamese government side, the government should 
support the domestic enterprises in providing informa-
tion on the pharmaceutical enterprises as well as the 
pharmaceutical industry of these four countries. These 
efforts are crucial for Vietnam’s enterprises to understand 
these biggest competitors to prepare themselves for at 
first competing successfully and then moving towards 
to mutual beneficial cooperation after the EVFTA enters 
into force.
Thirdly, the similar situation would occur with distri-
bution of Vietnam’s additional imports by pharmaceuti-
cal product. The Vietnamese government and enterprises 
should perceive this uneven distribution in import 
increases at disaggregated level to design appropriate 
business and investment strategy. It is because this une-
ven distribution would lead to different level of compe-
tition among product. At a disaggregated level, Vietnam 
would increase imports of HS 300490 from the EU at the 
biggest. Other products with high level of the increased 
imports would be HS 300420, HS 300410, HS 300432 
and HS 300630. Besides, Vietnam’s imports of HS 300510 
and HS 300590 would grow quite rapidly at around 16 
and 17  %. The above simulations results imply that the 
most vulnerable pharmaceutical product for Vietnam 
would be HS 300490, followed by HS 300420 and HS 
300410. Therefore, for the domestic enterprises whose 
product portfolio focuses on these three products, it is 
of great importance to well prepare by improving their 
production capacity and investing more in R&D to move 
towards to higher quality products and specialty medi-
cines. Taking advantage of the EVFTA to cooperate or 
create joint ventures with the EU companies in producing 
HS 300490, HS 300420 and HS 300410 is another option 
for the domestic enterprises. The Vietnamese govern-
ment should make policies supporting for these domes-
tic enterprises to improve their competitive capacity by 
developing pharmaceutical material areas and creating 
incentives for R&D activities in the pharmaceutical sec-
tor. For the domestic enterprises who focus on produc-
ing HS 300432, HS 300630, HS 300510 and HS 300590, 
the competition pressure they face with would be not as 
high as those who focus on HS 300490, HS 300410 and 
HS 300420. However, they should keep improving qual-
ity and variety of products and at the same time reduc-
ing the price to serve the domestic demand, especially 
for HS 300510 and HS 300910 that have been highly pro-
tected by the government for a long time. Otherwise, the 
threat to lose market to the EU pharmaceutical produc-
ers would possibly come true.
Fourthly, trade creation effect would be higher than 
trade diversion effect, representing 51.71  % of total 
trade effect in scenario 1. It implies that the EVFTA 
would improve welfare of Vietnam although the welfare 
improvement might be not too high. The welfare would 
potentially increase more when Vietnam removes tariffs 
for also the TPP and ASEAN + 3 nations because trade 
creation share increases to 57.32 % in scenario 2. In addi-
tion, the SMART simulation results show that if Viet-
nam only removes tariff for the EU, the EVFTA would 
negatively affect Vietnam’s integration in ASEAN and 
ASEAN + 3. Seven nations that Vietnam at present have 
FTAs with including India, Korea, Thailand, China, Aus-
tralia, Japan and Indonesia are among the top ten non-
EU countries that would suffer from the largest extent of 
trade diversion. This impact would deteriorate Vietnam’s 
ongoing integration effort in ASEAN. Therefore, Vietnam 
should promote the integration in the pharmaceutical 
sector with all three groups of nations, especially ASEAN 
and ASEAN’s key partners, to reduce trade diversion 
effect and raise the welfare of Vietnam by offering 0  % 
tariff rate for all of these countries, given that Vietnam 
should consider carefully the point of time to remove 
tariff for each group to avoid the sudden increase in its 
pharmaceutical imports.
Fifthly, if Vietnam removes pharmaceutical tariffs for 
all three groups of nations, besides the biggest competi-
tion from the EU, Vietnam should prepare for competi-
tion from other partners, especially the US and Australia. 
For HS 3004, the US and Australia would be other two 
big competitors; for HS 3005 would be South Korea 
and the US; and for HS 3006 the US. At the more disag-
gregated level, both TPP and ASEAN +  3 would affect 
Table 8 Top ten countries suffering from  trade diversion 
in scenario 1 (Unit: thousand USD) Source: SMART simula-
tion results
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considerably Vietnam’s import of HS 300490 from the 
EU, therefore, together with the EU, the US and Australia 
would be the biggest competitors. South Korea, followed 
by Thailand and China, would be the key destinations 
that would replace the EU’s pharmaceutical imports in 
Vietnam for HS 300410 and HS 300420. For HS 300432 
and HS 300630, the competition from Canada and the US 
respectively would be intensive.
Finally, the SMART results also imply that Vietnam 
would continuously rely on imports of pharmaceuticals 
from the key EU partners after the EVFTA like France, 
Germany, Italy and the UK as the increased imports of 
Vietnam from these countries are high in both value and 
growth rate. In the current context when the EU has 
been trying to overcome a wide range of economic and 
political difficulties, and the UK is standing in front of 
leaving or staying the EU, there would be possibility that 
the exports of the EU’s pharmaceutical producers, led by 
the German, French and UK enterprises, to the world 
could be instable. Accordingly, Vietnam will be forced to 
divert its imports to other pharmaceutical markets such 
as Australia, South Korea, China, and Thailand. This 
diversion may put the Vietnamese pharmaceutical mar-
ket into vulnerability and instability, affecting negatively 
on Vietnam’s economy due to the vital role of this prod-
uct to health and life of the people. Therefore, Vietnam 
on the one hand perceives the competition from the EU’s 
pharmaceuticals when the EVFTA comes into force, on 
the other hand should realize that this agreement would 
be an opportunity for Vietnam to increases the access 
to high-quality medicines, especially patent medicines, 
from the EU at a lower price in the possibility of declin-
ing exports from the EU in difficult period of time. On 
that ground, Vietnam should take measures to diversify 
its import markets and consider importing medicines 
from other European markets such as Slovenia, Czech 
Republic, Denmark and Ireland, whose trade creation 
take a high proportion in total trade affects as specified 
in SMART simulation results. These four countries have 
also been large pharmaceutical exporters in the world. 
This market diversification would enable Vietnam to less 
depend on the traditional key EU partners and improve 
welfare while taking opportunity from the EVFTA. It 
requires the Vietnamese enterprises to learn more about 
these markets to identify the types of specific medi-
cines that must be put priority to be imported given the 
strength of each market and Vietnam’s demand.
This paper has contributed to the existing literature by 
using the SMART model to analyze the impacts of the 
EVFTA on Vietnam’s imports of pharmaceuticals from 
the EU and propose some recommendations at a disag-
gregated level. However, it still has limitation and can be 
improved in the future. In fact, due to the non-existence 
of the empirical work to estimate the import demand 
elasticity, the import substitution elasticity and export 
supply elasticity for Vietnam, the paper used the elasticity 
values of the SMART model. Even though this approach 
has been commonly used by the previous studies, the 
future research would produce better results if using the 
elasticity values of the country whose pharmaceutical 
sectors are similar to Vietnam’s instead of adopting the 
SMART value. Moreover, this paper assessed impacts of 
tariff removal under the EVFTA. However, the non-tar-
iff barriers are also obstacles to the EU when exporting 
and investing in Vietnam in the pharmaceutical sector. 
Therefore, when the commitments between Vietnam and 
the EU for this sector are clearly made public, the future 
research should take into consideration of the impacts of 
both tariff and non-tariff barriers to provide more pre-
cise estimations on Vietnam’s changes in pharmaceutical 
imports of the EU.
Conclusions
By using the SMART model, this paper assessed ex-ante 
impacts of tariff removal under the EVFTA on Vietnam’s 
imports of pharmaceuticals from the EU based on two 
scenarios, which were constructed based on Vietnam’s 
tariff schedule disclosed so far under the EVFTA and the 
broader picture of on-going integration of the country in 
the pharmaceutical sector. In scenario 1, Vietnam would 
remove tariff for only pharmaceuticals imported from the 
EU while scenario 2 extends the coverage of tariff reduc-
tion to also ASEAN + 3 and TPP nations.
The results show that the EVFTA would result in 
an increase of about 3  % in Vietnam’s pharmaceuti-
cal imports from the EU and the EU would still be the 
biggest source of pharmaceuticals for Vietnam despites 
the efforts of Vietnam to integrate with the ASEAN + 3 
and TPP nations in this sector. The uneven distribution 
in Vietnam’s pharmaceutical imports from the EU by 
nation, pharmaceutical group and pharmaceutical prod-
uct would occur when the EVFTA is implemented. Most 
of the import increase would concentrate on France, 
Germany, the UK and Italy in terms of import source; 
on HS 3004 in term of pharmaceutical group; and on HS 
300490, 300420, HS 300410, HS 300432 and HS 300630 
in terms of pharmaceutical product. In addition, the 
EVFTA would potentially increase welfare of Vietnam 
because trade creation is bigger than trade diversion. 
However, the EVFTA would affect negatively Vietnam’s 
integration into ASEAN  +  3 if Vietnam only removes 
pharmaceutical tariff for the EU nations. The above find-
ings are of great importance because it provides strong 
evidence for Vietnam to pay more attention to the 
EVFTA and its impacts on pharmaceutical imports. The 
paper also suggests evidence-based implications for both 
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Vietnam’s government and enterprises to overcome the 
possible challenges as well as make the potential oppor-
tunities from the EVFTA come true.
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